Pre-Open Stock Movers:

Mesoblast Limited (Nasdaq: MESO) 43.5% HIGHER; announced additional results from the landmark DREAM-HF randomized controlled Phase 3 trial in 537 treated patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF) who received rexlemestrocel-L (REVASCOR®) or control sham. A single dose of rexlemestrocel-L resulted in substantial and durable reductions in heart attacks, strokes, and cardiac deaths. Since existing therapies have only minimal or no benefit on these endpoints, these notable outcomes may signal a breakthrough in addressing the principal unmet needs in patients with chronic heart failure. The results of this trial identify New York Heart Association (NYHA) class II HFrEF patients as the optimal target population for greatest rexlemestrocel-L treatment effect, and therefore a focus for registration and commercialization of rexlemestrocel-L in the largest market in heart failure.

Marathon Patent Group, Inc. (NASDAQ: MARA) 22.2% LOWER; falls on Bitcoin sell-off

Riot Blockchain, Inc. (NASDAQ: RIOT) 21.4% LOWER; falls on Bitcoin sell-off

Eli Lilly and Company (NYSE: LLY) 13.3% HIGHER; Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite measure of cognition and daily function in patients with early symptomatic Alzheimer's disease compared to placebo in results from Eli Lilly and Company's (NYSE: LLY) Phase 2 TRAILBLAZER-ALZ study. Donanemab met the primary endpoint of change from baseline to 76 weeks in the Integrated Alzheimer's Disease Rating Scale (iADRS), slowing decline by 32 percent relative to placebo, which was statistically significant. The iADRS is a clinical composite tool combining the cognitive measure ADAS-Cog13 and functional measure ADCS-iADL, two commonly used measures in Alzheimer's disease. Donanemab also showed consistent improvements in all prespecified secondary endpoints measuring cognition and function compared to placebo, but did not reach nominal statistical significance on every secondary endpoint.

500.com Limited (NYSE: WBAI) 11.6% HIGHER; announced that it has entered into a definitive purchase agreement (the "Agreement") with certain non-U.S. persons (the "Sellers") pursuant to which the Company expects to issue approximately US$14.4 million worth of its Class A ordinary shares as consideration to acquire bitcoin mining machines owned by the Sellers.

ODP (NASDAQ: ODP) 10.9% HIGHER; Staples Proposes To Acquire ODP (ODP) for $40/Share

Nio Inc, (NYSE: NIO) 10.4% HIGHER; may make mass market products under another marque, its chief executive said.

MicroStrategy Incorporated (NASDAQ: MSTR) 10.3% LOWER; falls on Bitcoin sell-off

GameStop Corp. (NYSE: GME) 8% HIGHER; today reported worldwide sales results for the nine-week holiday period ended January 2, 2021 reflecting a 4.8% increase in comparable store sales and a 309% increase in E-Commerce sales. Also announced that it has entered into an agreement with RC Ventures LLC that will advance the refreshment of the Companys Board of Directors. RC Ventures, which is one of the Companys largest stockholders, is managed by Ryan Cohen. The agreement provides for the immediate appointment of three new directors Alan Attal, Ryan Cohen and Jim Grube who will also stand for election on GameStops nine-member slate at the Companys 2021 Annual Meeting of Stockholders, which is expected to take place in June 2021.

Twitter, Inc. (NYSE: TWTR) 7.9% LOWER; falls as it permanently bans Trump

Gilead Sciences, Inc. (Nasdaq: GILD) 1.4% HIGHER; today announced the company has revised certain elements of its full year 2020 guidance. Total product sales guidance range is now $24.30 billion to $24.35 billion, reflecting increased Veklury (remdesivir) sales as hospitalization and treatment rates were higher than expected given the most recent COVID-19 surge. The prior range was $23-$23.5 billion and the consensus is $23.71 billion.

You May Also Be Interested In

• Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
• Equity Bancshares (EQBK) PT Raised to $38 at Piper Sandler
• Hibbett (HIBB) soars 18% on deal to sell to JD Sports for $1.08 billion